Fidaxomicin + Vancomycin

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile

Conditions

Clostridium Difficile

Trial Timeline

Nov 6, 2014 โ†’ May 5, 2016

About Fidaxomicin + Vancomycin

Fidaxomicin + Vancomycin is a approved stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02254967. Target conditions include Clostridium Difficile.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02254967ApprovedCompleted